COMPANY

Vaxiion Therapeutics

HQ: San Diego, CA source · vaxiion.com ↗ · West Coast

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab Urothelial Carcinoma of the Urinary Bladder VAX014

Timeline

Sep 16, 2025 Grant Government grant — SBIR: $306,265 (annual award, as published), announced Sep 16, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Nov 2, 2023 Trial start 1: Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors source ↗
May 10, 2019 Trial start 1: A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer source ↗

2027-08 (ESTIMATED) · 1 · Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors · NCT05901285

Estimated primary completion per ClinicalTrials.gov. Dates move.

Last 2 years.

Sep 16, 2025 Government grant — SBIR: $306,265 (annual award, as published), announced Sep 16, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT05901285	Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors	1	Recruiting	Nov 2, 2023	2027-08 (estimated)
NCT03854721	A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer	1	Completed	May 10, 2019	Mar 1, 2023 (actual)

Annual award amounts. Total $576K.

Jun 4, 2018 NIH award 1R43CA224450-01A1 FY2018: $232,276 awarded for that fiscal year; activity R43 (SBIR); PI GIACALONE, MATTHEW; recipient as written: VAXIION THERAPEUTICS, INC., SAN DIEGO, CA. Preclinical Evaluation of VAX014 source ↗
Sep 9, 2014 NIH award 3R43CA180403-01A1S1 FY2014: $69,725 awarded for that fiscal year; activity R43 (SBIR); PI GIACALONE, MATTHEW; recipient as written: VAXIION THERAPEUTICS, INC., SAN DIEGO, CA. Immunotherapeutic minicells for source ↗
Sep 23, 2013 NIH award 1R43CA180403-01A1 FY2013: $144,103 awarded for that fiscal year; activity R43 (SBIR); PI GIACALONE, MATTHEW; recipient as written: VAXIION THERAPEUTICS, INC., SAN DIEGO, CA. Immunotherapeutic minicells for source ↗
May 26, 2008 NIH award 1R43GM084517-01 FY2008: $130,000 awarded for that fiscal year; activity R43 (SBIR); PI GIACALONE, MATTHEW; recipient as written: VAXIION THERAPEUTICS, INC., SAN DIEGO, CA. Scaling up bacterial minicell prod source ↗